Novel mechanism of action behind the cardiometabolic effects of metformin

Scientists from the Laboratory of Pharmaceutical Pharmacology & Laboratory of Physical Organic Chemistry have published studies of metformin, the most widely prescribed oral medication for the treatment of type 2 diabetes. Research shows that metformin decreases plasma levels of cardiometabolic disease-related metabolite trimethylamine N-oxide (TMAO) in db/db mice with type 2 diabetes. The article is published in the journal Scientific Reports (IF=3.998, 2019).

J. Kuka, M. Videja; M. Makrecka-Kuka, J. Liepins, S. Grinberga, E. Sevostjanovs, K. Vilks, E. Liepinsh, M. Dambrova.
Metformin decreases bacterial trimethylamine production and trimethylamine N-oxide levels in db/db mice.
Scientific Reports 2020, 10, Article number: 14555, DOI: 10.1038/s41598-020-71470-4

This study was funded by the Latvian Council of Science project “Trimethylamine-N-oxide as a link between unhealthy diet and cardiometabolic risks” No. Izp-2018/1-0081.